# Reversal of metformin’s anti-proliferative effect in fission yeast efr3 and dnm1 (DRP1) mutants with elongated mitochondria

**Authors:** Ari Gillespie, Anne-Sophie Mehdorn, Tiffany Q. Lim, Tingting Wang, Bridget A. Mooney, Ashley J. Ovens, Ayla Orang, Jonathan S. Oakhill, Michael Z. Michael, Janni Petersen

PMC · DOI: 10.1038/s44324-024-00048-9 · Npj Metabolic Health and Disease · 2025-02-21

## TL;DR

This study shows that metformin's anti-proliferative effect in fission yeast can be reversed in mutants with elongated mitochondria, offering new insights into metformin's mechanism.

## Contribution

The study identifies Efr3 and dnm1 (DRP1) as key factors in metformin resistance, revealing a novel mitochondrial mechanism.

## Key findings

- Metformin's anti-proliferative effect in fission yeast is independent of AMPK.
- Efr3 deletion causes resistance to metformin through both AMPK-dependent and AMPK-independent pathways.
- Dnm1 (DRP1) mutants with elongated mitochondria are resistant to metformin, and metformin promotes mitochondrial fusion.

## Abstract

Metformin is a well-tolerated drug frequently prescribed for managing type 2 diabetes. Extended metformin use has been linked to a significant decrease in cancer incidence across both diabetic and non-diabetic populations. Here we investigate the anti-proliferative effects of metformin on fission yeast S. pombe. Our findings demonstrate that metformin’s inhibitory impact on cell proliferation is effective in the absence of AMP-activated protein kinase (AMPK). Using an unbiased genetic screen we identified the plasma membrane signalling scaffold Efr3, critical for phosphatidylinositol signalling and the generation of PI4Ps, as a key determinant of resistance to the anti-proliferative effect of metformin. Deletion of efr3 resulted in both AMPK-dependent and AMPK-independent resistance to metformin. We show that Efr3 does not influence cell proliferation by controlling Ras1 activity or its cellular localization in yeast. We observe that dnm1 (DRP1) mutants with elongated mitochondria are also resistant to the anti-proliferative effect of metformin and that metformin treatment promotes mitochondrial fusion. Metabolic measurements after prolonged metformin exposure demonstrated a reduction in respiration in both wild type and the efr3 deletion, however, that reduction is less pronounced in the efr3 deletion, which also contained elongated mitochondria. It is likely that mitochondrial fusion enhances yeast fitness in response to metformin exposure. Together we provide a new perspective on the cellular response to metformin.

## Linked entities

- **Genes:** efr-3 (Protein EFR3 homolog) [NCBI Gene 174042], DNM1 (dynamin 1) [NCBI Gene 1759], PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], ras-1 (R-RAS related) [NCBI Gene 174875]
- **Proteins:** efr-3 (Protein EFR3 homolog), CRMP1 (collapsin response mediator protein 1)
- **Chemicals:** metformin (PubChem CID 4091)
- **Diseases:** type 2 diabetes (MONDO:0005148), cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** type 2 diabetes (MESH:D003924), cancer (MESH:D009369), diabetic (MESH:D003920)
- **Chemicals:** Metformin (MESH:D008687), phosphatidylinositol (MESH:D010716), PI4Ps (-)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Schizosaccharomyces pombe (fission yeast, species) [taxon 4896]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11845315/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11845315/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC11845315/full.md

---
Source: https://tomesphere.com/paper/PMC11845315